Every announcement Lupin has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Price
₹2225
Market Cap
₹1.02L Cr
Revenue TTM
₹29,966.58 Cr
P/E (TTM)
18.4×
Sector 45.61×
Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.
Lupin Subsidiary VISUfarma Signs ₹832 Cr Licensing Deal with Visus for YUVEZZI in Europe
Lupin Limited subsidiary VISUfarma B.V. signs ₹832 Cr deal with Visus Therapeutics to commercialize YUVEZZI in Europe, targeting the presbyopia treat…
Lupin Launches Sugammadex Injection in US Following FDA Approval for Bridion Generic
Lupin Limited launches Sugammadex Injection in the US, a bioequivalent to Merck's Bridion® for surgical recovery, as the company reports 62.5% annual…
Lupin Reports Record ₹27,958 Cr Revenue in FY26; US Business Surges 40 Percent
Lupin Ltd reports record FY26 revenue of ₹27,958 cr, a 23% YoY increase. US sales crossed $1.3bn while EBITDA margins hit 29.7% on complex generic la…
Lupin Limited Reports 32% Q4 Revenue Growth as FY26 EBITDA Surges 68%
Lupin Limited achieves record FY26 results with 32% Q4 revenue growth and 29.7% EBITDA margins driven by US generic exclusivity and strong India chro…
Track Lupin in real time
ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Lupin files something material.
Start Free — 15-day trial